FDA Authorizes Digital Therapeutic for Sleep Disturbance in PTSD
NightWare is a smartwatch application that uses the Apple Watch and Apple iPhone platform.
Anxiety/OCD
MPR Weekly Dose Podcast Episode 52
This week we cover new Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok ‘challenge’; And FDA grants Nucala new approval. Also we look at this week’s developments in drugs in the pipeline.
FDA Requires Boxed Warning Update for Benzodiazepines
Benzodiazepines are widely used to treat a variety of conditions including anxiety disorders, insomnia and seizures.
Escitalopram Reduces Symptoms of Anxiety in Teens With GAD
Increasing CYP2C19 metabolism linked to reductions in escitalopram Cmax, AUC.
Differences in Anxiety, Depression According to Current and Former Smoking Status
Both stable current smokers and individuals who had quit exhibited significantly less anxiety but more depression.
FDA: Guidance on Digital Therapeutics for Psychiatric Disorders During COVID-19
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
FDA Bans Electrical Stimulation Devices for Self-Injurious, Aggressive Behavior
The use of electrical stimulation devices (ESDs) to treat self-injurious or aggressive behavior has been banned by the Food and Drug Administration (FDA).
Intranasal Therapy Fast-Tracked for Social Anxiety Disorder
The FDA has granted Fast Track designation to PH94B (aloradine; VistaGen Therapeutics), a central nervous system neuroactive nasal spray for the on-demand treatment of social anxiety disorder.
Diet Pill, Laxative Use in Women Tied to Later Eating Disorder Dx
Odds of incident eating disorder diagnosis up with use of diet pill, laxative for weight control
MPR Weekly Dose Podcast: Episode 11
This week we talk about the recall of an anti-anxiety med; Possible withdrawal of Makena; New MS treatment approved; IUD approved for up to six years; and time of day when meds taken could affect CVD risk.
